Inclusion Body Myositis Treated with Alemtuzumab

Inclusion body myositis (IBM) is a chronic inflammatory myopathy with a progressive course. It is more common in the later years of life and usually presents with limb weakness. We present the case of a patient who developed proximal weakness in the lower limbs and, four years later, facial asymmetr...

Full description

Bibliographic Details
Main Authors:	Juliana Sá, João Costelha, Antonio Marinho
Format:	Article
Language:	English
Published:	SMC MEDIA SRL 2019-12-01
Series:	European Journal of Case Reports in Internal Medicine
Subjects:	inclusion body myositis alemtuzumab myopathy treatment
Online Access:	https://www.ejcrim.com/index.php/EJCRIM/article/view/1368

id	doaj-a359b5f745ef4ace85840785407c6724
record_format	Article
spelling	doaj-a359b5f745ef4ace85840785407c67242020-11-25T02:37:02ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942019-12-0110.12890/2019_0013681368Inclusion Body Myositis Treated with AlemtuzumabJuliana Sá0João Costelha1Antonio Marinho2Centro Hospitalar Cova da Beira, Covilhã, Portugalnidade Local de Saúde do Alto Minho, EPE, PortugalCentro Hospitalar do Porto, Porto, PortugalInclusion body myositis (IBM) is a chronic inflammatory myopathy with a progressive course. It is more common in the later years of life and usually presents with limb weakness. We present the case of a patient who developed proximal weakness in the lower limbs and, four years later, facial asymmetry. Blood analysis revealed high lactate dehydrogenase and creatinine kinase values. The diagnosis was obtained through muscle biopsy which met the histological criteria for IBM. The patient started treatment with alemtuzumab, leading to stabilisation of the symptoms in two years.https://www.ejcrim.com/index.php/EJCRIM/article/view/1368inclusion body myositisalemtuzumabmyopathytreatment
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Juliana Sá João Costelha Antonio Marinho
spellingShingle	Juliana Sá João Costelha Antonio Marinho Inclusion Body Myositis Treated with Alemtuzumab European Journal of Case Reports in Internal Medicine inclusion body myositis alemtuzumab myopathy treatment
author_facet	Juliana Sá João Costelha Antonio Marinho
author_sort	Juliana Sá
title	Inclusion Body Myositis Treated with Alemtuzumab
title_short	Inclusion Body Myositis Treated with Alemtuzumab
title_full	Inclusion Body Myositis Treated with Alemtuzumab
title_fullStr	Inclusion Body Myositis Treated with Alemtuzumab
title_full_unstemmed	Inclusion Body Myositis Treated with Alemtuzumab
title_sort	inclusion body myositis treated with alemtuzumab
publisher	SMC MEDIA SRL
series	European Journal of Case Reports in Internal Medicine
issn	2284-2594
publishDate	2019-12-01
description	Inclusion body myositis (IBM) is a chronic inflammatory myopathy with a progressive course. It is more common in the later years of life and usually presents with limb weakness. We present the case of a patient who developed proximal weakness in the lower limbs and, four years later, facial asymmetry. Blood analysis revealed high lactate dehydrogenase and creatinine kinase values. The diagnosis was obtained through muscle biopsy which met the histological criteria for IBM. The patient started treatment with alemtuzumab, leading to stabilisation of the symptoms in two years.
topic	inclusion body myositis alemtuzumab myopathy treatment
url	https://www.ejcrim.com/index.php/EJCRIM/article/view/1368
work_keys_str_mv	AT julianasa inclusionbodymyositistreatedwithalemtuzumab AT joaocostelha inclusionbodymyositistreatedwithalemtuzumab AT antoniomarinho inclusionbodymyositistreatedwithalemtuzumab
_version_	1724797123877142528

Inclusion Body Myositis Treated with Alemtuzumab

Similar Items